Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 180

The DOI matches its Crossref record.

Gemcitabine versus bacille Calmette‐Guérin after initial bacille Calmette‐Guérin failure in non‐muscle‐invasive bladder cancer: A multicenter prospective randomized trial

Open access
Di Lorenzo, Giuseppe, Perdonà, Sisto, Damiano, Rocco, Faiella, Adriana, Cantiello, Francesco, Pignata, Sandro, Ascierto, Paolo, Simeone, Ester, De Sio, Marco, Autorino, Riccardo · 2010 · Cancer

Abstract

BACKGROUND: The efficacy of intravesical gemcitabine was evaluated compared with repeated administration of bacille Calmette‐Guérin (BCG) after BCG failure in high‐risk, non‐muscle‐invasive bladder cancer (BC). METHODS: In this multicenter, prospective, randomized, phase 2 trial, eligible patients were those with high‐risk non‐muscle‐invasive BC, failing 1 course of BCG therapy. All patients were randomly allocated to Group A, receiving intravesical gemcitabine (at a dose of 2000 mg/50 mL) twice weekly for 6 consecutive weeks and then weekly for 3 consecutive weeks at 3, 6, and 12 months, or Group B, receiving intravesical BCG (Connaught strain, 81 mg/50 mL) over a 6‐week induction course and each week for 3 weeks at 3, 6, and 12 months. Outcome measures were recurrence rate, time to first recurrence, and progression rate. Treatment‐related complications were also evaluated. RESULTS: Eighty participants were enrolled, 40 for each group 52.5% in Group A developed disease recurrence versus 87.5% of those in Group B (P = .002). There was no statistically significant difference in mean time to the first recurrence (Group A, 3.9 months; Group B, 3.1 months; P = .09). Kaplan‐Meier analysis of 2‐year recurrence‐free survival showed significant differences between Group A and B (19% and 3%, respectively, P < .008). Seven of 21 (33%) patients in Group A and 13 of 35 (37.5%) patients in Group B had disease progression and underwent radical cystectomy (P = .12). Both intravesical administrations were generally well tolerated. CONCLUSIONS: Gemcitabine might represent a second‐line treatment option after BCG failure in high‐risk non‐muscle‐invasive BC patients. Cancer 2010. © 2010 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.24914

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 180

Metadata

Authors
Di Lorenzo, G., Perdonà, S., Damiano, R., Faiella, A., Cantiello, F., Pignata, S., Ascierto, P., Simeone, E., De Sio, M., & Autorino, R.
Venue
Cancer
Publisher
Wiley
Published
2010-04-06
Volume
116
Issue
8
Pages
1893-1900
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2042179480
Cited by
180
References
0
FWCI
10.25
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gemcitabine versus bacille Calmette‐Guérin after initial bacille Calmette‐Guérin failure in non‐muscle‐invasive bladder cancer: A multicenter prospective randomized trial. https://app.cochat.ai/papers/10.1002/cncr.24914
The paper
Di Lorenzo, G., Perdonà, S., Damiano, R., Faiella, A., Cantiello, F., Pignata, S., Ascierto, P., Simeone, E., De Sio, M., & Autorino, R. (2010). Gemcitabine versus bacille Calmette‐Guérin after initial bacille Calmette‐Guérin failure in non‐muscle‐invasive bladder cancer: A multicenter prospective randomized trial. Cancer. https://doi.org/10.1002/cncr.24914

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.